Identifying novel therapeutic agents using xenograft models of pediatric cancer.

ABSTRACT: In the USA, the overall cure rate for all childhood cancers is seventy percent, and in many patients that ultimately fail curative therapy, initial responses to current multimodality treatments (surgery, radiation therapy and chemotherapy) is good, with overall 5-year event-free survival approaching 80 %. However, current approaches to curative therapy result in significant morbidity and long-term sequelae, including cardiac dysfunction and cognitive impairment. Furthermore, dose-intensive chemotherapy with conventional agents has not significantly improved outcomes for patients that present with advanced or metastatic disease. Classical cytotoxic agents remain the backbone for curative therapy of both hematologic and solid tumors of childhood. While 'molecularly' targeted agents have show

SUBMITTER: Kurmasheva RT 

PROVIDER: S-EPMC4966996 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature